TCGA-A2-A04U-01A-11R-A115-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 88
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- MYC_TARGETS_V1+0.490
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.350
- NOTCH_SIGNALING+0.330
- OXIDATIVE_PHOSPHORYLATION+0.260
- SPERMATOGENESIS+0.200
- DNA_REPAIR+0.190
- MTORC1_SIGNALING+0.150
- UV_RESPONSE_UP+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.480
- UV_RESPONSE_DN-0.410
- ESTROGEN_RESPONSE_EARLY-0.400
- TGF_BETA_SIGNALING-0.390
- ANDROGEN_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.320
- ESTROGEN_RESPONSE_LATE-0.310
- IL6_JAK_STAT3_SIGNALING-0.310
- INFLAMMATORY_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A574-01A-11R-A29R-07 | — | E | 0.868 |
| 2 | SRR10900561 | — | — | 0.861 |
| 3 | TCGA-B6-A0IQ-01A-11R-A034-07 | — | E | 0.858 |
| 4 | SRR25617909 | — | E | 0.857 |
| 5 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.854 |
| 6 | ERR2598250 | fetal | fetal | 0.851 |
| 7 | ERR4976600 | — | A | 0.851 |
| 8 | TCGA-B6-A402-01A-11R-A239-07 | — | E | 0.847 |
| 9 | SRR650168 | — | — | 0.847 |
| 10 | ERR2208888 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |